Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony Sabin

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Statistics in Biopharmaceutical Research|April 1, 2014
A Quantitative Process for Enhancing End of Phase 2 DecisionsTony Sabin, James Matcham, Sarah Bray, et al.
Pharmaceutical Statistics|December 14, 2011
A statistician's perspective on biomarkers in drug developmentMartin Jenkins, Aiden Flynn, Trevor Smart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancerLuis Paz-Ares, Beatrix Bálint, Richard H de Boer, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Statistics in Biopharmaceutical Research|April 1, 2014
A Quantitative Process for Enhancing End of Phase 2 DecisionsTony Sabin, James Matcham, Sarah Bray, et al.
Pharmaceutical Statistics|December 14, 2011
A statistician's perspective on biomarkers in drug developmentMartin Jenkins, Aiden Flynn, Trevor Smart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 2, 2013
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancerLuis Paz-Ares, Beatrix Bálint, Richard H de Boer, et al.
Pageof 1